Insider Trading July 24, 2026 06:01 AM

Travelers Executive Michael Klein Executes $2.2 Million Stock Disposition Amid Mixed Analyst Sentiment

Executive Vice President Michael Klein's recent stock sales coincide with varied analyst outlooks on The Travelers Companies, reflecting both earnings momentum and valuation concerns.

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
TRV

Michael Frederick Klein, Executive Vice President and President of Personal Insurance at The Travelers Companies, Inc., executed a series of stock transactions on July 21, 2026, resulting in the sale of 6,000 shares valued at approximately $2.2 million. The sales occurred in two separate transactions, with shares sold at weighted average prices of $364.9033 and $366.1189 respectively. Prior to the sales, Klein acquired 6,000 shares by exercising stock options at $139.83 per share. The transaction occurs as Travelers stock trades near its 52-week high of $378.66, currently at $376.37, following a 46% return over the past year. While recent earnings exceeded analyst estimates, prompting price target upgrades from several firms, Goldman Sachs downgraded the stock to Sell with a $350 target, citing valuation concerns.

Travelers Executive Michael Klein Executes $2.2 Million Stock Disposition Amid Mixed Analyst Sentiment
TRV
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Travelers EVP Michael Klein sold 6,000 shares of company stock on July 21, 2026, for approximately $2.2 million, with the sales occurring in two separate transactions at weighted average prices of $364.9033 and $366.1189 per share.
  • Prior to the sales, Mr. Klein acquired 6,000 shares by exercising stock options at $139.83 per share, totaling $838,980, with options exercisable as of February 2, 2024, and expiring on February 2, 2031.
  • Travelers recently reported strong second-quarter earnings that surpassed analyst estimates, prompting price target upgrades from Truist Securities, Raymond James, and Keefe, Bruyette & Woods, while Goldman Sachs downgraded the stock to Sell due to valuation concerns.

Michael Frederick Klein, serving as Executive Vice President and President of Personal Insurance at The Travelers Companies, Inc., completed a significant stock disposition on July 21, 2026. The transaction involved the sale of 6,000 shares of the company's common stock, generating a total value of approximately $2.2 million. The sales were executed through two distinct transactions. In the first instance, 125 shares were disposed of at a weighted average price of $364.9033 per share, with individual sale prices ranging from $364.72 to $365.03. The second transaction saw the sale of an additional 5,875 shares at a weighted average price of $366.1189 per share, with prices ranging from $365.798 to $366.275.


The timing of these sales occurs as Travelers stock trades near its 52-week high of $378.66, with shares currently valued at $376.37. The stock has delivered a 46% return over the past year. According to InvestingPro analysis, Travelers appears overvalued at current levels. InvestingPro offers 15 additional exclusive tips for TRV subscribers.


Prior to these sales on the same day, Mr. Klein acquired 6,000 shares of Travelers common stock by exercising stock options at an exercise price of $139.83 per share, totaling $838,980. These options were exercisable as of February 2, 2024, and are set to expire on February 2, 2031. Following these transactions, Mr. Klein directly holds 45,124.787 shares of Travelers common stock. He also indirectly holds 1,895.088 shares through a 401(k) Plan. Additionally, Mr. Klein beneficially owns 30,037 derivative securities in the form of stock options.


In other recent news, Travelers Companies Inc. reported strong second-quarter earnings, surpassing estimates from several analysts. BofA Securities noted that Travelers' earnings exceeded their estimate of $5.45 per share and the Street consensus of $5.37 per share, highlighting a favorable reserve development. Following these results, several firms adjusted their outlooks for the company. Truist Securities raised its price target to $425, citing earnings momentum and increasing its full-year 2026 earnings per share estimate to $34.10. Similarly, Raymond James increased its price target to $430, maintaining a Strong Buy rating, and emphasized the company's profitability outlook. Keefe, Bruyette & Woods also raised its price target to $373 and increased earnings estimates for 2026 and 2027. Despite these positive assessments, Goldman Sachs downgraded the stock to Sell, setting a price target of $350, due to concerns about valuation. These developments reflect a varied analyst outlook on Travelers Companies Inc., with some focusing on earnings strength and others expressing caution about valuation.


Travelers Companies
Follow
Analyze TRV
Included in our AI-picked strategies
Review strategies376.37▲+4.29(+1.15%)Closed378.20▲+1.83(+0.49%)Pre Market·06:01:531D1W1M6M1Y5YMaxCreated with Highcharts 11.4.814:0015:0016:0017:0018:0019:00370372374376378Analyze TRVThis article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Is your TRV trade worth the risk?Before you click "buy," know exactly where to set your stop-loss. Our Vision AI literally "sees" your TRV chart and delivers a complete risk management plan—entry, stop-loss, and profit target—in under 60 seconds.Protect your downside. Validate every trade. Invest smarter.July Sale - 60% Off InvestingPro

Risks

  • Goldman Sachs downgraded the stock to Sell with a price target of $350, citing concerns about valuation, indicating potential downside risk for investors.
  • InvestingPro analysis suggests Travelers appears overvalued at current levels, highlighting valuation concerns that may impact future stock performance.
  • The mixed analyst outlook, with some firms raising price targets and others expressing caution, reflects uncertainty regarding the company's future valuation and market perception.

More from Insider Trading

Rani Therapeutics Director Mir A Imran Acquires $24,839 in Stock Amid Clinical and Corporate Developments Jul 24, 2026 Cytokinetics EVP Fady Malik Sells Stock Amid Myqorzo Launch Momentum Jul 24, 2026 Acrivon Therapeutics CLO Mary Miller Sells $1,008 in Company Stock Jul 24, 2026 Kaltura Officer Eynav Azaria Executes $8,971 Stock Sale Under Pre-Arranged Plan Jul 24, 2026 Rhinebeck Bancorp Director Loughlin Acquires $149,120 in Stock Amid Structural Transition Jul 24, 2026